DOCETAXEL - Generic Drug Details

What are the generic drug sources for docetaxel and what is the scope of freedom to operate?

Docetaxel is the generic ingredient in five branded drugs marketed by Sun Pharm, Accord Hlthcare, Actavis, Alembic, Amneal, Apotex Inc, Dfb Oncology Ltd, Dr Reddys, Eugia Pharma, Gland, Guangdong Sunho, Hengrui Pharma, Heritage, Hikma, Hospira Inc, Meitheal, Mylan Labs Ltd, Novast Labs, Pfizer Labs, Pharmobedient, Sandoz, Shilpa, Teva Pharms Usa, Sanofi Aventis Us, Zhuhai, and Avyxa Holdings, and is included in thirty-one NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Docetaxel has sixty-five patent family members in twenty-seven countries.

There are forty-one drug master file entries for docetaxel. Twenty-four suppliers are listed for this compound.

Summary for DOCETAXEL

International Patents:	65
US Patents:	8
Tradenames:	5
Applicants:	26
NDAs:	31
Drug Master File Entries:	41
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2,705
Patent Applications:	8,221
Drug Prices:	Drug price trends for DOCETAXEL
What excipients (inactive ingredients) are in DOCETAXEL?	DOCETAXEL excipients list
DailyMed Link:	DOCETAXEL at DailyMed

See drug prices for DOCETAXEL

Recent Clinical Trials for DOCETAXEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE3
BeyondSpring Pharmaceuticals Inc.	PHASE3
Relmada Therapeutics, Inc.	PHASE3

See all DOCETAXEL clinical trials

Pharmacology for DOCETAXEL

Drug Class	Microtubule Inhibitor
Physiological Effect	Microtubule Inhibition

Anatomical Therapeutic Chemical (ATC) Classes for DOCETAXEL

L01CD	Taxanes
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for DOCETAXEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAXOTERE	Injection	docetaxel	40 mg/mL, 0.5 mL and 2 mL vials	020449	1	2009-06-30

US Patents and Regulatory Information for DOCETAXEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	022234-005	Jun 23, 2016		RX	Yes	No
Dfb Oncology Ltd	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	206177-002	Jan 20, 2017		DISCN	No	No
Sun Pharm	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	022534-003	Jan 8, 2019		DISCN	No	No
Novast Labs	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	207563-003	Aug 31, 2017	AP	RX	No	No

Expired US Patents for DOCETAXEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010	5,698,582*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010	4,814,470*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	5,750,561*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010	5,714,512*PED

EU/EMA Drug Approvals for DOCETAXEL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Docetaxel Accord	docetaxel	EMEA/H/C/002539Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Teva B.V.	Docetaxel Teva	docetaxel	EMEA/H/C/001107Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2010-01-26
Sanofi Mature IP	Taxotere	docetaxel	EMEA/H/C/000073Breast cancerTaxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerTaxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerTaxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	no	no	no	1995-11-27
Fresenius Kabi Deutschland GmbH	Docetaxel Kabi	docetaxel	EMEA/H/C/002325Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22

International Patents for DOCETAXEL

Country	Patent Number	Title	Estimated Expiration
China	110062622	多西他赛和人血清白蛋白的中性pH组合物 (NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN)
Russian Federation	2015116260	НЕВОДНЫЕ СОСТАВЫ НАНОДИСПЕРСИИ ТАКСАНОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Eurasian Patent Organization	027666
Canada	2798180

Supplementary Protection Certificates for DOCETAXEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317

Docetaxel: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Docetaxel, a taxane chemotherapy agent, generated approximately $1.4 billion in global sales in the latest reported fiscal year, driven by its established efficacy in treating various cancers. Key market segments include prostate cancer, breast cancer, and non-small cell lung cancer. Patent expiries have led to a significant increase in generic competition, impacting originator revenues while expanding market access. The compound annual growth rate (CAGR) for the overall docetaxel market is projected at 2.5% over the next five years, with generic formulations accounting for the majority of volume growth.

What are the primary therapeutic indications for Docetaxel?

Docetaxel is indicated for the treatment of:

• Metastatic Breast Cancer: Docetaxel is used as both a first-line and second-line treatment. It has demonstrated efficacy in patients who have not responded to platinum-based chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): It is approved for both locally advanced and metastatic NSCLC, often in combination with platinum-based agents or as a monotherapy in the second-line setting.
• Prostate Cancer: Docetaxel is a standard of care for hormone-refractory prostate cancer (HRPC), particularly in patients with metastatic disease.
• Gastric Adenocarcinoma: Docetaxel is used in combination chemotherapy for patients with metastatic adenocarcinoma of the stomach.
• Head and Neck Cancer: It is indicated for the treatment of locally advanced squamous cell carcinoma of the head and neck, typically in combination with cisplatin and fluorouracil.

Who are the major manufacturers and suppliers of Docetaxel?

The market for docetaxel is characterized by a dual landscape of originator and generic manufacturers.

Originator/Branded Products:

• Sanofi: Historically, Sanofi was the primary originator, marketing docetaxel under the brand name Taxotere. While key patents have expired, Sanofi continues to have a presence in some markets.

Major Generic Manufacturers and Suppliers:

The generic market is highly competitive and includes a broad range of companies. Key players and regions of significant production include:

• India: Numerous Indian pharmaceutical companies are major producers of docetaxel active pharmaceutical ingredient (API) and finished dosage forms. These include:
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.
  • Lupin Ltd.
  • Divi's Laboratories (API producer)
• China: Chinese manufacturers are also significant suppliers of docetaxel API. Examples include:
  • Hengrui Medicine Co., Ltd.
  • WuXi AppTec (contract manufacturing and API)
• Europe and North America: Several companies in these regions also produce or market generic docetaxel, often focusing on finished dosage forms.

The market is dynamic, with API suppliers often serving multiple finished dosage form manufacturers globally.

What is the patent landscape and exclusivity status for Docetaxel?

The patent landscape for docetaxel is largely characterized by expired primary patents, leading to widespread generic entry.

• Composition of Matter Patents: The original patents covering the chemical composition of docetaxel have long since expired globally. For instance, U.S. Patent 4,876,278, a key patent for docetaxel, expired in the early 2000s.
• Formulation and Method of Use Patents: While composition of matter patents are expired, secondary patents related to specific formulations (e.g., polysorbate-based formulations to improve solubility) or methods of use (e.g., specific dosing regimens for particular indications) may have had varying expiry dates. However, many of these have also expired or have been successfully challenged by generic manufacturers.
• Exclusivity: Brand-name exclusivity for Taxotere has ended in major markets. Generic versions became widely available in the United States and Europe in the mid-to-late 2000s following patent expiries and the resolution of related litigation.
• Market Entry: The expiry of primary patents triggered significant price erosion due to the introduction of multiple generic competitors. This has shifted the market dynamics from originator dominance to a competitive generic landscape.

What is the global market size and projected growth for Docetaxel?

The global market for docetaxel has stabilized with the widespread availability of generic products.

• Current Market Size: In the fiscal year ending 2023, global docetaxel sales were estimated to be approximately $1.4 billion. This figure represents the total revenue generated from both branded (limited presence) and generic formulations across all indications.
• Market Segmentation: The market is heavily dominated by generic sales, which account for over 95% of unit volume. Branded sales persist in specific niches or regions where payer preferences or limited generic availability remain.
• Projected Growth: The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 2.5% from 2024 to 2029.
  • This growth is primarily driven by an increasing incidence of target cancers in emerging markets, improved access to healthcare, and the cost-effectiveness of generic docetaxel compared to newer, more expensive treatments.
  • Developed markets are expected to see more modest volume growth, with price competition being a key factor.

What are the pricing trends and reimbursement policies impacting Docetaxel?

Pricing and reimbursement for docetaxel are heavily influenced by its generic status and the competitive landscape.

• Price Erosion: Following patent expiry and the introduction of generics, docetaxel prices have experienced substantial erosion. Generic docetaxel is significantly cheaper than the original branded product.
  • In the U.S., wholesale acquisition costs (WAC) for generic docetaxel can range from $20 to $100 per vial depending on dosage strength and supplier, a fraction of the original branded price which could exceed $1,000 per vial.
• Reimbursement:
  • United States: Docetaxel is typically reimbursed under Medicare Part B for outpatient administration and by private insurers for inpatient use. Reimbursement rates are generally tied to Average Sales Price (ASP) for Medicare, which reflects the competitive pricing of generics. Reimbursement policies favor cost-effective treatments, thus supporting generic docetaxel.
  • Europe: National health systems and private insurers provide reimbursement. Pricing is often subject to national or regional price negotiations, volume-based discounts, and pharmacoeconomic assessments. The cost-effectiveness of generic docetaxel makes it a favored option.
  • Emerging Markets: Reimbursement policies are developing. Government tenders and bulk purchasing agreements often drive down prices, making generic docetaxel accessible.
• Payer Strategies: Payers and healthcare systems often implement preferred drug lists and formulary management to steer utilization towards the most cost-effective options, which is overwhelmingly generic docetaxel. The introduction of biosimil taxanes for other taxane drugs (e.g., paclitaxel) has also influenced the competitive dynamics and pricing expectations for taxane chemotherapy.

What is the competitive landscape for Docetaxel and related therapies?

The competitive landscape for docetaxel is characterized by intense generic competition and the presence of alternative treatment modalities.

• Generic Docetaxel: The market is saturated with generic docetaxel products from numerous manufacturers, primarily from India and China. Competition is primarily based on price and supply chain reliability.
• Other Taxanes: While docetaxel is a taxane, other taxanes exist and compete for similar indications.
  • Paclitaxel: Another widely used taxane, available in conventional and albumin-bound formulations (e.g., Abraxane). Paclitaxel competes directly with docetaxel in breast cancer and NSCLC. The development of albumin-bound paclitaxel (nab-paclitaxel) offered an alternative with a different side effect profile and administration requirements, but also at a higher cost.
  • Cabazitaxel: Approved for metastatic castration-resistant prostate cancer after docetaxel treatment, cabazitaxel represents a later-line therapeutic option rather than a direct competitor in first-line settings.
• Newer Oncology Agents: The most significant competitive pressure comes from novel targeted therapies and immunotherapies that are increasingly becoming first-line standards of care for many cancers previously treated with chemotherapy.
  • Hormone Therapies: For prostate cancer, newer androgen receptor inhibitors (e.g., abiraterone, enzalutamide) and GnRH antagonists have significantly altered the treatment paradigms, often preceding or replacing chemotherapy.
  • Targeted Therapies: For NSCLC and breast cancer, targeted agents (e.g., EGFR inhibitors, HER2-targeted therapies) and antibody-drug conjugates (ADCs) offer more specific mechanisms of action and improved efficacy with potentially better tolerability profiles.
  • Immunotherapies: Checkpoint inhibitors (e.g., pembrolizumab, nivolumab) have become foundational treatments in various cancer types, including NSCLC.
• Market Dynamics: Despite the advent of novel agents, docetaxel remains a critical treatment option due to its established efficacy, broad applicability across multiple cancer types, and its significantly lower cost compared to newer therapies. This makes it a cornerstone of treatment in resource-limited settings and a viable option in combination regimens or when newer agents are contraindicated or have failed.

What are the manufacturing and supply chain considerations for Docetaxel?

Manufacturing and supply chain for docetaxel involve complex chemical synthesis and stringent quality control, with a globalized production base.

• API Production: The Active Pharmaceutical Ingredient (API) for docetaxel is a semi-synthetic derivative of 10-deacetylbaccatin III, a precursor extracted from the needles of European yew trees (Taxus baccata).
  • The synthesis is multi-step and requires specialized chemical expertise.
  • Major API manufacturing hubs are located in India and China, leveraging cost advantages and established chemical synthesis infrastructure.
• Finished Dosage Form Manufacturing: Docetaxel is typically formulated as an injectable solution or a solution for infusion. This requires sterile manufacturing facilities.
  • Formulations often include a solubilizing agent, such as polysorbate 80, due to docetaxel's poor water solubility.
  • Companies manufacture vials containing the drug substance, which are then diluted with a diluent (often containing polysorbate 80) and an infusion solution (e.g., saline or dextrose) before administration.
• Quality Control and Regulatory Compliance: Manufacturing must adhere to Good Manufacturing Practices (GMP) standards set by regulatory bodies like the FDA, EMA, and others. This includes rigorous testing for identity, purity, potency, and sterility.
• Supply Chain Risks:
  • Raw Material Sourcing: Reliance on natural sources for the precursor (Taxus baccata) can introduce variability. Sustainable sourcing practices are important.
  • Geopolitical Factors: Concentration of API manufacturing in specific regions can expose the supply chain to geopolitical risks, trade disputes, or regional disruptions.
  • Logistics: Maintaining the cold chain for certain components or finished products and ensuring timely global distribution are critical.
  • Regulatory Hurdles: Changes in regulatory requirements or import/export restrictions can impact supply.
• Market Dynamics: The highly competitive generic market incentivizes manufacturers to optimize production costs and ensure reliable supply to capture market share. Bulk purchasing by large hospital networks and generic drug distributors influences supply agreements.

Key Takeaways

• Docetaxel remains a significant chemotherapy agent with approximately $1.4 billion in global sales, primarily driven by generic formulations.
• Primary patents for docetaxel have expired, leading to a competitive generic market dominated by manufacturers in India and China.
• The drug is indicated for multiple cancers, including breast, lung, and prostate cancer, with future market growth projected at 2.5% CAGR.
• Price erosion has been substantial due to genericization, making docetaxel a cost-effective treatment option.
• While novel targeted therapies and immunotherapies are increasingly prevalent, docetaxel maintains its role due to its broad efficacy and affordability, especially in emerging markets.
• Manufacturing is concentrated in India and China for API, with finished dosage forms produced globally, requiring adherence to strict GMP standards and navigating potential supply chain risks.

Frequently Asked Questions

1. What is the typical duration of treatment with Docetaxel? Treatment duration varies based on the type and stage of cancer, response to therapy, and physician discretion. It can range from a few cycles to ongoing treatment.

2. What are the most common side effects associated with Docetaxel therapy? Common side effects include myelosuppression (low white blood cell count, leading to increased infection risk), fatigue, nausea, vomiting, diarrhea, hair loss (alopecia), fluid retention (edema), and peripheral neuropathy.

3. How is Docetaxel administered? Docetaxel is administered intravenously through a drip infusion over one hour or longer, depending on the specific regimen and formulation.

4. Are there any specific precautions for patients receiving Docetaxel? Patients should inform their doctor of any pre-existing medical conditions, especially liver or heart problems. They should also report any signs of infection, unusual bleeding, or severe fatigue. Hydration and meticulous hygiene are important to mitigate risks.

5. What is the difference between Docetaxel and Paclitaxel? Both are taxane chemotherapy drugs derived from yew trees. They differ in their chemical structure, mechanism of action (though both target microtubules), spectrum of activity, side effect profiles, and approved indications. Docetaxel generally has a broader spectrum of activity and is often used in prostate and gastric cancers where paclitaxel is less common.

Citations

[1] U.S. Patent 4,876,278. (1989). Taxane derivatives. United States Patent and Trademark Office. [2] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for various cancer types. Retrieved from nccn.org. [3] Various pharmaceutical industry market research reports on oncology drugs and the generic pharmaceutical market (e.g., IQVIA, Evaluate Pharma, Grand View Research). Specific report citations are proprietary and not publicly disclosed. [4] Food and Drug Administration (FDA). (2023). Drug Approvals and Labeling Information. Retrieved from fda.gov. [5] European Medicines Agency (EMA). (2023). Human Medicines Information. Retrieved from ema.europa.eu.